Raising Venture Capital for Hardware and Deep Tech Companies
Hardware and deep tech companies raise against technical milestones rather than growth curves, because the risk being retired is whether the thing works and can be built at cost. That changes the evidence investors want, lengthens the cycle between rounds, and makes non-dilutive funding and IP position materially more important than in software.
What is actually being underwritten
In software the dominant question is usually whether anyone wants the product and whether you can reach them efficiently. Building it is assumed to be tractable.
In robotics, physical AI, and most deep tech, that assumption inverts. Demand is often obvious, sometimes visible in existing spending, and the open question is whether the thing can be made to work reliably, at a cost that leaves a business, on a timeline anyone can finance.
So the pitch is structured differently. Instead of demonstrating demand and describing a go-to-market motion, you are demonstrating that a specific technical risk has been retired and naming the next one you intend to retire with this money.
That framing also tells you what evidence matters. A working demonstration under realistic conditions rather than in a controlled setting. A measured performance number and a description of what limits it. A credible account of how the cost curve moves as volume grows. And an honest list of what could still go wrong, which experienced deep tech investors weigh heavily because founders who cannot name their remaining risks are usually the ones who have not found them yet.
Demonstrations beat descriptions
Video of the system operating in an uncontrolled environment does more than any slide. Investors in this space have seen many demonstrations that worked once, so the details that build credibility are the unglamorous ones: how often it fails, what happens when it does, how long it ran, and who was allowed to touch it.
Raise around milestones, not around runway
In a capital-intensive company, the raise should be sized and timed to a milestone that makes the next raise possible, rather than to a number of months.
That means naming the milestone precisely. Not "advance the prototype" but the specific capability, reliability level, or cost point that changes what a reasonable person believes about the company. The test is whether an investor at the next stage would agree that reaching it retires a risk they care about.
Build in schedule margin, because hardware timelines slip for reasons software timelines do not: supply lead times, fabrication cycles, certification queues, and the physical world declining to cooperate. A plan with no margin is a plan to raise again from a weak position, and raising while behind schedule in this sector is expensive.
It also helps to sequence milestones so that each one is independently meaningful. If your plan only produces a result at the end of an eighteen month effort, you have no intermediate evidence to show anyone, which makes a bridge round harder exactly when you might need one.
Non-dilutive capital is not a consolation prize
Deep tech companies typically raise more rounds before revenue than software companies do, and each round dilutes. Over a long development cycle that compounds into a materially different founder position at the same stage.
Which makes non-dilutive sources strategically important rather than a fallback. Government and agency grants, research programs, development contracts with a customer who wants the capability to exist, and revenue from adjacent services that use the same technology all extend runway without selling ownership.
There are real tradeoffs. Grant applications consume founder time and arrive on their own schedule. Development contracts can pull the roadmap toward one customer's requirements, which is a strategic cost even when the revenue is welcome. Some programs come with restrictions on IP or on where work must be performed, and those terms deserve reading rather than skimming.
Used deliberately, this capital does something dilutive money cannot: it lets you reach a stronger technical position before you set a price, which improves every subsequent round.
IP, timelines, and the investors who fund this
IP position matters more here than in software. Where advantage rests on a genuine technical insight rather than on execution speed, patents and trade secret discipline are part of the defensibility argument, and investors will examine ownership carefully. That makes clean assignment from every contributor, including university collaborators and contractors, a diligence item you cannot resolve quickly if it is wrong.
University involvement adds a specific complication worth handling early: if the technology originated in a lab, the institution may hold rights or require a license, and the terms of that license are foundational to the company rather than a detail.
The investor set is narrower and worth researching. Generalist funds sometimes participate but usually price capital-intensive timelines poorly against their fund model. Investors who specialize in this space understand milestone-based progress, expect longer holding periods, and ask better questions. A smaller list of well matched conversations outperforms a broad list here more than in software.
This is general information about how these raises are structured, not legal advice. IP ownership, university license terms, and grant conditions have consequences specific to your facts and should be reviewed with counsel before they are locked in.
Frequently asked questions
- How is raising for hardware different from software?
- The risk being underwritten is technical rather than commercial. Demand is often evident, and the open question is whether the system can work reliably at a cost that supports a business. So rounds are raised against milestones that retire specific technical risks rather than against growth metrics that do not exist yet.
- What evidence do deep tech investors want?
- A demonstration under realistic rather than controlled conditions, a measured performance figure with an explanation of what limits it, a credible account of how cost moves with volume, and an honest list of remaining risks. Founders who cannot name their open risks are usually the ones who have not found them.
- Should hardware startups pursue grants and non-dilutive funding?
- Often yes, because deep tech companies raise more rounds before revenue and that dilution compounds. Grants, research programs, and development contracts extend runway without selling ownership. The tradeoffs are real: application time, schedules you do not control, roadmap pull from a single customer, and occasional IP conditions.
- Does IP matter more for deep tech fundraising?
- Yes. Where advantage rests on technical insight rather than execution speed, patents and trade secret practice form part of the defensibility argument and investors examine ownership closely. Clean assignment from every contributor matters, and any university origin brings license terms that are foundational rather than administrative.